BNT329

PreclinicalSmall molecule

BioNTech

BNT329 is one of 5 small molecule programs targeting Advanced Solid Cancers. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Advanced Solid CancersRecruiting

Advanced Solid CancersPreclinical

Recruiting

Competition

Competitive Landscape

6 competitors in Advanced Solid Cancers

#DrugCompanyPhaseTrials

Opdivo

Bristol-Myers Squibb

Phase 2

3 2

Yervoy

Bristol-Myers Squibb

Phase 2

2 3

Copanlisib Hydrochloride

NNational Cancer Institute (NCI)

Phase 2

1 4

ND-003

SShenzhen NewDEL Biotech, Co., Ltd

Phase 1

1 5

BNT329

BioNTech

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2030

PreclinicalRecruiting

Advanced Solid Cancers

NCT07186842

Clinical

Trials by Indication[1]

Advanced Solid Cancers1 trial

First-in-human, Open-label, Multi-site, Phase I/IIa, Dose Escalation Trial With Expansion Cohorts to Evaluate Safety and Preliminary Efficacy of BNT329 in Participants With Advanced Solid Tumors Known to Express CA19-9

Recruiting· BioNTech logo

BioNTech·Preclinical·NCT07186842·245 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for BNT329. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BNT329 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BNT329. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — BioNTech company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: BioNTech

BNT329

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2030

Trials by Indication[1]

Advanced Solid Cancers1 trial

References

Drug Info

Quick Facts

Related News